ATX101 Successful Phase 1

AUROBAC today announces the successful completion of its Phase 1 clinical trial (NCT07107802) evaluating ATX101.

ATX101 is a potential first-in-class therapy designed to address shock, organ failure, and mortality associated with sepsis.

Completion of the Phase 1 trial marks an important milestone for AUROBAC and reflects the strength of its strategic partnership with Boehringer Ingelheim.

Backed by the continued commitment of its founding organizations, AUROBAC is advancing its mission to transform the treatment of severe bacterial infections and their life-threatening complications, including sepsis and septic shock.

Know more